Ignite Creation Date:
2025-12-24 @ 4:41 PM
Ignite Modification Date:
2026-01-27 @ 1:33 AM
Study NCT ID:
NCT02614066
Status:
COMPLETED
Last Update Posted:
2024-11-19
First Post:
2015-11-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Sponsor:
Kite, A Gilead Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-03-07
Start Date Type:
ACTUAL
Primary Completion Date:
2022-07-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-03
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-23
First Submit QC Date:
None
Study First Post Date:
2015-11-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-09-09
Results First Submit QC Date:
None
Results First Post Date:
2021-11-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-30
Last Update Post Date:
2024-11-19
Last Update Post Date Type:
ACTUAL